Ciro Franzese1,2, Rossana Ingargiola3, Stefano Tomatis1, Nicola Alessandro Iacovelli3, Giancarlo Beltramo4, Pierfrancesco Franco5, Pierluigi Bonomo6, Isa Bossi Zanetti4, Angela Argenone7, Domenico Cante8, Domenico Attilio Romanello3, Daniela Musio9, Francesca De Felice9, Carlo Furlan10, Marta Scorsetti1,2, Ester Orlandi3,11. 1. Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy. 2. Department of Biomedical Sciences, Humanitas University, Milan, Italy. 3. Radiation Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. 4. Radiation Oncology, Cyberknife Center, Centro Diagnostico Italiano, Milan, Italy. 5. Department of Oncology, Radiation Oncology, School of Medicine, University of Turin, Turin, Italy. 6. Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. 7. Radiation Oncology Unit, Istituto Nazionale per la cura e lo studio dei tumori, Fondazione G. Pascale, Napoli, Italy. 8. Radiotherapy Department, Ivrea Community Hospital, Ivrea (Turin), Italy. 9. Department of Radiotherapy, Policlinico Umberto I "Sapienza" University of Rome, Rome, Italy. 10. Department of Radiation Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCSS, Aviano, Italy. 11. Radiation Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Abstract
OBJECTIVES: The role of radiotherapy (RT) for oligometastases is currently established in different oncological settings but data on salivary gland cancer (SGC) are lacking. We evaluated the role of RT in oligometastatic SGC patients, focusing on stereotactic body radiation therapy (SBRT). MATERIALS AND METHODS: We performed a retrospective, multicentric study of oligometastatic SGC treated with palliative RT or SBRT. Endpoints included response evaluation and local control (LC). RESULTS: Between 2006 and 2016, 64 patients were collected from 9 Italian Cancer Centers, on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Head and Neck Working Group. 37 patients (57.8%) were suffering from adenoid cystic carcinoma (ACC) and 27 patients (42.2%) had non-ACC. Thirty-four patients underwent palliative RT (53,1%), and 30 received SBRT (46,9%). Most common metastatic sites were bone for palliative RT and lung for SBRT. Among patients treated with SBRT, an objective response or a stability was observed in all treated lesions. After a median follow-up of 29.2 months (range 2.3-117.1), LC at 12 months was 57.5% for patients treated with SBRT and was higher in ACC subgroup. CONCLUSION: We confirmed the potential role of SBRT in the management of oligometastatic SGC patients to control limited burden of disease considering the absence of effective systemic therapies.
OBJECTIVES: The role of radiotherapy (RT) for oligometastases is currently established in different oncological settings but data on salivary gland cancer (SGC) are lacking. We evaluated the role of RT in oligometastatic SGC patients, focusing on stereotactic body radiation therapy (SBRT). MATERIALS AND METHODS: We performed a retrospective, multicentric study of oligometastatic SGC treated with palliative RT or SBRT. Endpoints included response evaluation and local control (LC). RESULTS: Between 2006 and 2016, 64 patients were collected from 9 Italian Cancer Centers, on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Head and Neck Working Group. 37 patients (57.8%) were suffering from adenoid cystic carcinoma (ACC) and 27 patients (42.2%) had non-ACC. Thirty-four patients underwent palliative RT (53,1%), and 30 received SBRT (46,9%). Most common metastatic sites were bone for palliative RT and lung for SBRT. Among patients treated with SBRT, an objective response or a stability was observed in all treated lesions. After a median follow-up of 29.2 months (range 2.3-117.1), LC at 12 months was 57.5% for patients treated with SBRT and was higher in ACC subgroup. CONCLUSION: We confirmed the potential role of SBRT in the management of oligometastatic SGC patients to control limited burden of disease considering the absence of effective systemic therapies.
Authors: Ciro Franzese; Ausilia Teriaca; Armando De Virgilio; Giuseppe Mercante; Giuseppe Spriano; Marta Scorsetti Journal: J Cancer Res Clin Oncol Date: 2021-09-16 Impact factor: 4.553